Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

Original reporting
Published Nov 10, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36% — source image
Decision brief

The 30-second read

$LEGNBearishMed
01

Why it matters

The mixed data and flat sales suggest near‑term downside risk, but long‑term growth guidance and expanding European footprint provide upside catalysts.

02

Market read

The earnings call provides fresh guidance and trial data that can move LEGN and influence the broader BCMA CAR‑T sector.

03

What to watch

Potential for improved margins from manufacturing efficiencies and expanding ex‑U.S. market share may offset near‑term sales flatness.

Relevance 8/10Novelty 8/10Timing: post‑earnings Q3 2026 call

Background

Legend Biotech discussed Q3 2026 performance of its CAR‑T product CARVYKTI, trial updates for LB2501, and outlook for upcoming CAR‑T programs.

Company-level read

Ticker impact

$LEGNBearishHigh confidence
Context

Q3 2026 earnings call disclosed flat U.S. CARVYKTI sales, guidance for double‑digit growth in 2027, and mixed LB2501 dose‑response data.

Expected impact

likely pressure as investors price in slower U.S. growth and trial uncertainty

Evidence & confidence

First disclosure of sales flattening and new dose‑response data; guidance is modest and market may react negatively until data improves.

Market effects

Highlights competitive pressure from bispecifics like TECVAYLI and may prompt re‑rating of BCMA CAR‑T sector peers.

European launch delays could affect regional biotech exposure.

Trial data and guidance may influence broader immunotherapy investment sentiment.

Counterpoint

If the 2027 double‑digit growth materializes, the stock could rally on upside potential despite short‑term setbacks.

Key entities

  • Legend Biotech Corp

    US‑listed biotech developing BCMA CAR‑T therapies.

  • Johnson & Johnson

    Collaboration partner for LB2505 program.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.

$LEGNHigh

Legend Biotech Corp (LEGN): Financial results for Q3 2026

Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress